Kaleibe

Kaleibe is a private gene therapy biotechnology company created within Replay's product-company model to develop therapies for genetic brain disorders. The company is focused on using a high-payload herpes simplex virus vector platform, synHSV, to deliver large genes that exceed the cargo limits of adeno-associated virus approaches. Its initial pipeline has been described as targeting genetic Parkinson's disease and Friedreich's ataxia, two neurologic disorders with known genetic drivers and substantial unmet need. Kaleibe was launched in December 2022 and is associated with scientific founders including Richard Wade-Martins, Howard J. Federoff, and Joe Glorioso. Publicly available information suggests the company remains in the preclinical stage, with no disclosed clinical trials or marketed products.